PTSD

A panelist discusses how posttraumatic stress disorder (PTSD) alters key brain regions, such as the amygdala and hippocampus, with genetic predisposition, severity of trauma exposure, and lack of social support serving as critical risk factors that can influence both the likelihood of developing the condition and its neurobiological impact.

A panelist discusses how posttraumatic stress disorder (PTSD) permeates modern society at multiple levels, from individuals coping with personal trauma to collective trauma responses that shape community behaviors and social structures.

Let’s compare treatment risks when managing mixed states.

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

Traumatic life events are common among individuals who experience psychosis. Here's how best to assess and treat.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Patients who have experienced a perinatal loss are at increased risk of MDD, anxiety disorders, and trauma-related disorders.

There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.

Enter your email to check out this complicated case!

Is the complex posttraumatic stress disorder diagnosis being used to avoid the diagnosis of borderline personality disorder?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

While new treatment options in the PTSD space can be exciting, we cannot lose sight of the treatments that are already readily available.

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

Is PTSD overdiagnosed?

A phase 3 clinical trial participant shares her thoughts on MDMA-assisted psychotherapy and her trial experience.

Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.

How can you best identify and manage pediatric PTSD?

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

Whether a patient has a diagnosis of cPTSD, BPD, or some combination of both, treatment should be considered multifaceted and overlapping. Learn more in this Special Report article.

An understanding of evolving risk factors and pathophysiology is vital to optimal clinical management of anxiety disorders and PTSD.

For those who have experienced trauma and suffer a subsequent mental health disorder, ongoing research is identifying psychotherapies, medications, and lifestyle changes that can help.

The 2024 American Society of Clinical Psychopharmacology Annual Meeting brought together researchers and clinicians to engage in discussion, education, and dissemination of research findings and new methodologies.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

Psychiatric Times wants to help you, as clinicians, support every patient.

Prepare your patients for the Fourth of July with expert tips from Roger Rivera, FNP, PMHNP, DNP, on managing risky behaviors, adherence distractions, PTSD-related triggers, and sensory overload during the holiday.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

Here are highlights from the week in Psychiatric Times.